Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(8):1052–1057. doi: 10.1054/bjoc.2000.1715

Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53

Y Umano 1, T Tsunoda 1,2, H Tanaka 1, K Matsuda 1, H Yamaue 1, H Tanimura 1
PMCID: PMC2363851  PMID: 11308253

Abstract

Mutations in the p53 gene are the most common genetic alterations found in human tumours, and these mutations result in high levels of p53 protein in the tumour cells. Since the expression levels of wild-type p53 in nonmalignant tissue are usually much lower in contrast, the p53 protein is an attractive target for cancer immunotherapy. We tested p53 encoded HLA-A24 binding peptides for their capacity to elicit anti-tumour cytotoxic T lymphocytes (CTL) in vitro. These peptides were in murine p53-derived cytotoxic peptides, which were being presented to CTL by H-2K d and H-2K b molecules, because the HLA-A24 peptide binding motifs were similar to the H-2K d and H-2K b. For CTL induction, we used CD8+T lymphocytes from the peripheral blood mononuclear cells (PBMC) of healthy donors and the peptides from pulsed dendritic cells as antigen-presenting cells. We identified the peptide, p53-161 (AIYKQSQHM), which was capable of eliciting CTL lines that lysed tumour cells expressing HLA-A24 and p53. The effectors lysed C1RA24 cells (p53+, HLA-A*2402 transfectant), but not their parental cell lines C1R (p53+, HLA-A,B null cell). These results strongly indicate that the CTL exerts cytotoxic activity in HLA-A24's restricted manner. The identification of this novel p53 epitope for CTL offers the possibility to design and develop specific immunotherapeutic approaches for treating tumours with p53 mutation in HLA-A24-positive patients. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: p53, CTL, HLA-A24, peptide

Full Text

The Full Text of this article is available as a PDF (82.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Butterfield L. H., Koh A., Meng W., Vollmer C. M., Ribas A., Dissette V., Lee E., Glaspy J. A., McBride W. H., Economou J. S. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999 Jul 1;59(13):3134–3142. [PubMed] [Google Scholar]
  2. Campo E., de la Calle-Martin O., Miquel R., Palacin A., Romero M., Fabregat V., Vives J., Cardesa A., Yague J. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res. 1991 Aug 15;51(16):4436–4442. [PubMed] [Google Scholar]
  3. Celis E., Tsai V., Crimi C., DeMars R., Wentworth P. A., Chesnut R. W., Grey H. M., Sette A., Serra H. M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2105–2109. doi: 10.1073/pnas.91.6.2105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chikamatsu K., Nakano K., Storkus W. J., Appella E., Lotze M. T., Whiteside T. L., DeLeo A. B. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res. 1999 Jun;5(6):1281–1288. [PubMed] [Google Scholar]
  5. DeLeo A. B., Jay G., Appella E., Dubois G. C., Law L. W., Old L. J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A. 1979 May;76(5):2420–2424. doi: 10.1073/pnas.76.5.2420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fujie T., Tahara K., Tanaka F., Mori M., Takesako K., Akiyoshi T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer. 1999 Jan 18;80(2):169–172. doi: 10.1002/(sici)1097-0215(19990118)80:2<169::aid-ijc1>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  7. Gnjatic S., Cai Z., Viguier M., Chouaib S., Guillet J. G., Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol. 1998 Jan 1;160(1):328–333. [PubMed] [Google Scholar]
  8. Harris C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996 Oct 16;88(20):1442–1455. doi: 10.1093/jnci/88.20.1442. [DOI] [PubMed] [Google Scholar]
  9. Hernández J., Lee P. P., Davis M. M., Sherman L. A. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol. 2000 Jan 15;164(2):596–602. doi: 10.4049/jimmunol.164.2.596. [DOI] [PubMed] [Google Scholar]
  10. Kikuchi M., Nakao M., Inoue Y., Matsunaga K., Shichijo S., Yamana H., Itoh K. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer. 1999 May 5;81(3):459–466. doi: 10.1002/(sici)1097-0215(19990505)81:3<459::aid-ijc21>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  11. Kubo R. T., Sette A., Grey H. M., Appella E., Sakaguchi K., Zhu N. Z., Arnott D., Sherman N., Shabanowitz J., Michel H. Definition of specific peptide motifs for four major HLA-A alleles. J Immunol. 1994 Apr 15;152(8):3913–3924. [PubMed] [Google Scholar]
  12. Lee K. H., Wang E., Nielsen M. B., Wunderlich J., Migueles S., Connors M., Steinberg S. M., Rosenberg S. A., Marincola F. M. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999 Dec 1;163(11):6292–6300. [PubMed] [Google Scholar]
  13. Marchand M., Weynants P., Rankin E., Arienti F., Belli F., Parmiani G., Cascinelli N., Bourlond A., Vanwijck R., Humblet Y. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer. 1995 Dec 11;63(6):883–885. doi: 10.1002/ijc.2910630622. [DOI] [PubMed] [Google Scholar]
  14. Maric M., Liu Y. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1alpha-expressing tumor: linkage between inflammation and specific immunity. Cancer Res. 1999 Nov 1;59(21):5549–5553. [PubMed] [Google Scholar]
  15. Mayordomo J. I., Loftus D. J., Sakamoto H., De Cesare C. M., Appasamy P. M., Lotze M. T., Storkus W. J., Appella E., DeLeo A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med. 1996 Apr 1;183(4):1357–1365. doi: 10.1084/jem.183.4.1357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McCarty T. M., Liu X., Sun J. Y., Peralta E. A., Diamond D. J., Ellenhorn J. D. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res. 1998 Jun 15;58(12):2601–2605. [PubMed] [Google Scholar]
  17. Morse M. A., Deng Y., Coleman D., Hull S., Kitrell-Fisher E., Nair S., Schlom J., Ryback M. E., Lyerly H. K. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 1999 Jun;5(6):1331–1338. [PubMed] [Google Scholar]
  18. Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998 Mar;4(3):328–332. doi: 10.1038/nm0398-328. [DOI] [PubMed] [Google Scholar]
  19. Nukaya I., Yasumoto M., Iwasaki T., Ideno M., Sette A., Celis E., Takesako K., Kato I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999 Jan 5;80(1):92–97. doi: 10.1002/(sici)1097-0215(19990105)80:1<92::aid-ijc18>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  20. Oiso M., Eura M., Katsura F., Takiguchi M., Sobao Y., Masuyama K., Nakashima M., Itoh K., Ishikawa T. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer. 1999 May 5;81(3):387–394. doi: 10.1002/(sici)1097-0215(19990505)81:3<387::aid-ijc12>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  21. Romani N., Gruner S., Brang D., Kämpgen E., Lenz A., Trockenbacher B., Konwalinka G., Fritsch P. O., Steinman R. M., Schuler G. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994 Jul 1;180(1):83–93. doi: 10.1084/jem.180.1.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Dudley M. E., Schwarz S. L., Spiess P. J. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998 Mar;4(3):321–327. doi: 10.1038/nm0398-321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Roth J., Dittmer D., Rea D., Tartaglia J., Paoletti E., Levine A. J. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4781–4786. doi: 10.1073/pnas.93.10.4781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Röpke M., Hald J., Guldberg P., Zeuthen J., Nørgaard L., Fugger L., Svejgaard A., Van der Burg S., Nijman H. W., Melief C. J. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14704–14707. doi: 10.1073/pnas.93.25.14704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Salgaller M. L., Marincola F. M., Cormier J. N., Rosenberg S. A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 1996 Oct 15;56(20):4749–4757. [PubMed] [Google Scholar]
  26. Schwarz R. E., McCarty T. M., Peralta E. A., Diamond D. J., Ellenhorn J. D. An orthotopic in vivo model of human pancreatic cancer. Surgery. 1999 Sep;126(3):562–567. [PubMed] [Google Scholar]
  27. Storkus W. J., Zeh H. J., 3rd, Salter R. D., Lotze M. T. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):94–103. [PubMed] [Google Scholar]
  28. Tanaka F., Fujie T., Tahara K., Mori M., Takesako K., Sette A., Celis E., Akiyoshi T. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res. 1997 Oct 15;57(20):4465–4468. [PubMed] [Google Scholar]
  29. Theobald M., Biggs J., Dittmer D., Levine A. J., Sherman L. A. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):11993–11997. doi: 10.1073/pnas.92.26.11993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Theobald M., Biggs J., Hernández J., Lustgarten J., Labadie C., Sherman L. A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med. 1997 Mar 3;185(5):833–841. doi: 10.1084/jem.185.5.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Theobald M., Ruppert T., Kuckelkorn U., Hernandez J., Häussler A., Ferreira E. A., Liewer U., Biggs J., Levine A. J., Huber C. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med. 1998 Sep 21;188(6):1017–1028. doi: 10.1084/jem.188.6.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vierboom M. P., Nijman H. W., Offringa R., van der Voort E. I., van Hall T., van den Broek L., Fleuren G. J., Kenemans P., Kast W. M., Melief C. J. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med. 1997 Aug 29;186(5):695–704. doi: 10.1084/jem.186.5.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Vissers J. L., De Vries I. J., Schreurs M. W., Engelen L. P., Oosterwijk E., Figdor C. G., Adema G. J. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 1999 Nov 1;59(21):5554–5559. [PubMed] [Google Scholar]
  34. Walter E. A., Greenberg P. D., Gilbert M. J., Finch R. J., Watanabe K. S., Thomas E. D., Riddell S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995 Oct 19;333(16):1038–1044. doi: 10.1056/NEJM199510193331603. [DOI] [PubMed] [Google Scholar]
  35. Wang F., Bade E., Kuniyoshi C., Spears L., Jeffery G., Marty V., Groshen S., Weber J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999 Oct;5(10):2756–2765. [PubMed] [Google Scholar]
  36. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998 Jun;292(3):435–445. doi: 10.1007/s004410051072. [DOI] [PubMed] [Google Scholar]
  37. Yang D., Nakao M., Shichijo S., Sasatomi T., Takasu H., Matsumoto H., Mori K., Hayashi A., Yamana H., Shirouzu K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res. 1999 Aug 15;59(16):4056–4063. [PubMed] [Google Scholar]
  38. Yanuck M., Carbone D. P., Pendleton C. D., Tsukui T., Winter S. F., Minna J. D., Berzofsky J. A. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res. 1993 Jul 15;53(14):3257–3261. [PubMed] [Google Scholar]
  39. Yu Z., Liu X., McCarty T. M., Diamond D. J., Ellenhorn J. D. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J Surg Res. 1997 May;69(2):337–343. doi: 10.1006/jsre.1997.5058. [DOI] [PubMed] [Google Scholar]
  40. Zhou X., Wong S., Walter J., Jacks T., Eisen H. N. Increased generation of CD8+ T cell clones in p53 mutant mice. J Immunol. 1999 Apr 1;162(7):3957–3960. [PubMed] [Google Scholar]
  41. van der Burg S. H., Ras E., Drijfhout J. W., Benckhuijsen W. E., Bremers A. J., Melief C. J., Kast W. M. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol. 1995 Dec;44(4):189–198. doi: 10.1016/0198-8859(95)00105-0. [DOI] [PubMed] [Google Scholar]
  42. van der Burg S. H., Visseren M. J., Brandt R. M., Kast W. M., Melief C. J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol. 1996 May 1;156(9):3308–3314. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES